Liquidia Key Executives
This section highlights Liquidia's key executives, including their titles and compensation details.
Find Contacts at Liquidia
(Showing 0 of )
Liquidia Earnings
This section highlights Liquidia's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Date:
May 12, 2025
Time:
Before Market
Est. EPS:
$-0.42
Status:
Unconfirmed
Last Earnings Results
Date:
March 19, 2025
EPS:
$-0.46
Est. EPS:
$-0.38
Revenue:
$2.92M
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|---|---|---|---|---|
| Read Transcript | Q4 | 2024 | 2025-03-19 | $-0.38 | $-0.46 |
| Read Transcript | Q3 | 2024 | 2024-11-13 | $-0.37 | $-0.37 |
| Read Transcript | Q2 | 2024 | 2024-08-08 | N/A | N/A |
| Read Transcript | Q1 | 2024 | 2024-05-14 | N/A | N/A |
| Read Transcript | Q4 | 2023 | 2024-03-13 | $-0.23 | $-0.42 |
| Read Transcript | Q3 | 2023 | 2023-11-07 | $-0.20 | $-0.24 |
| Read Transcript | Q2 | 2023 | 2023-08-10 | $-0.17 | $-0.36 |
| Read Transcript | Q1 | 2023 | 2023-05-06 | N/A | N/A |
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.
Healthcare
Biotechnology
$13.72
Stock Price
$1.17B
Market Cap
200.00K
Employees
Morrisville, NC
Location
Financial Statements
Access annual & quarterly financial statements for Liquidia, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Revenue | $14.00M | $17.49M | $15.94M | $12.85M | $739.63K |
| Cost of Revenue | $5.88M | $2.89M | $2.86M | $3.02M | $237.71K |
| Gross Profit | $8.12M | $14.60M | $13.08M | $9.83M | $501.92K |
| Gross Profit Ratio | 58.00% | 83.49% | 82.06% | 76.48% | 67.86% |
| Research and Development Expenses | $47.84M | $43.24M | $19.43M | $20.52M | $32.22M |
| General and Administrative Expenses | $81.57M | $44.74M | $32.41M | $23.11M | $27.37M |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $81.57M | $44.74M | $32.41M | $23.11M | $27.37M |
| Other Expenses | $- | $- | $- | $- | $- |
| Operating Expenses | $129.41M | $87.98M | $51.85M | $43.63M | $59.59M |
| Cost and Expenses | $135.29M | $90.87M | $54.70M | $46.65M | $59.83M |
| Interest Income | $7.65M | $3.47M | $1.09M | $33.44K | $184.36K |
| Interest Expense | $12.49M | $6.27M | $2.34M | $815.04K | $858.00K |
| Depreciation and Amortization | $2.20M | $2.18M | $3.96M | $5.85M | $3.12M |
| EBITDA | $-115.71M | $-70.05M | $-34.72M | $-27.91M | $-55.79M |
| EBITDA Ratio | -826.74% | -400.57% | -217.88% | -217.18% | -7542.79% |
| Operating Income | $-121.29M | $-73.38M | $-38.77M | $-33.80M | $-59.09M |
| Operating Income Ratio | -866.63% | -419.62% | -243.30% | -262.94% | -7989.03% |
| Total Other Income Expenses Net | $-9.10M | $-5.12M | $-2.25M | $-781.65K | $-673.64K |
| Income Before Tax | $-130.39M | $-78.50M | $-41.02M | $-34.58M | $-59.76M |
| Income Before Tax Ratio | -931.65% | -448.89% | -257.39% | -269.02% | -8080.11% |
| Income Tax Expense | $- | $- | $-2.65M | $-4.80M | $-2.27M |
| Net Income | $-130.39M | $-78.50M | $-38.37M | $-29.78M | $-57.49M |
| Net Income Ratio | -931.65% | -448.89% | -240.76% | -231.70% | -7772.99% |
| EPS | $-1.66 | $-1.21 | $-0.63 | $-0.60 | $-1.70 |
| EPS Diluted | $-1.66 | $-1.21 | $-0.63 | $-0.60 | $-1.70 |
| Weighted Average Shares Outstanding | 78.71M | 64.99M | 60.96M | 49.68M | 33.89M |
| Weighted Average Shares Outstanding Diluted | 78.71M | 64.99M | 60.96M | 49.68M | 33.89M |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.92M | $4.45M | $3.66M | $2.97M | $4.53M | $3.68M | $4.79M | $4.49M | $5.36M | $3.17M | $3.92M | $3.49M | $3.22M | $3.18M | $3.38M | $3.08M | $739.63K | $- | $- | $- |
| Cost of Revenue | $1.35M | $1.56M | $1.49M | $1.76M | $1.27M | $570.00K | $671.00K | $654.00K | $694.00K | $740.00K | $731.00K | $694.00K | $725.93K | $889.51K | $713.74K | $693.74K | $237.71K | $- | $- | $- |
| Gross Profit | $1.56M | $2.88M | $2.17M | $1.22M | $3.26M | $3.11M | $4.12M | $3.84M | $4.67M | $2.42M | $3.19M | $2.80M | $2.49M | $2.29M | $2.66M | $2.39M | $501.92K | $- | $- | $- |
| Gross Profit Ratio | 53.58% | 64.82% | 59.20% | 40.92% | 71.95% | 84.50% | 85.98% | 85.44% | 87.05% | 76.62% | 81.34% | 80.13% | 77.42% | 72.02% | 78.86% | 77.50% | 67.86% | 0.00% | 0.00% | 0.00% |
| Research and Development Expenses | $16.48M | $11.89M | $9.42M | $9.77M | $12.55M | $7.44M | $17.70M | $5.28M | $4.98M | $4.51M | $5.22M | $4.73M | $5.38M | $4.49M | $4.60M | $6.05M | $5.25M | $7.66M | $8.49M | $10.82M |
| General and Administrative Expenses | $21.20M | $20.18M | $19.94M | $20.25M | $17.14M | $10.56M | $9.24M | $7.79M | $6.19M | $6.74M | $6.94M | $12.54M | $8.47M | $4.88M | $4.42M | $5.34M | $11.17M | $7.15M | $5.23M | $3.82M |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $21.20M | $20.18M | $19.94M | $20.25M | $17.14M | $10.56M | $9.24M | $7.79M | $6.19M | $6.74M | $6.94M | $12.54M | $8.47M | $4.88M | $4.42M | $5.34M | $11.17M | $7.15M | $5.23M | $3.82M |
| Other Expenses | $- | $- | $- | $- | $-278.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Operating Expenses | $37.67M | $32.07M | $29.36M | $30.02M | $29.70M | $18.00M | $26.94M | $13.07M | $11.16M | $11.26M | $12.16M | $17.27M | $13.85M | $9.37M | $9.02M | $11.39M | $16.42M | $14.81M | $13.72M | $14.65M |
| Cost and Expenses | $39.02M | $33.64M | $30.86M | $31.77M | $30.97M | $18.57M | $27.61M | $13.72M | $11.86M | $12.00M | $12.89M | $17.96M | $14.58M | $10.26M | $9.73M | $12.08M | $16.65M | $14.81M | $13.72M | $14.65M |
| Interest Income | $2.10M | $1.81M | $1.85M | $1.88M | $948.00K | $862.00K | $734.00K | $922.00K | $662.00K | $359.00K | $65.00K | $4.00K | $3.91K | $3.88K | $4.88K | $20.77K | $28.51K | $34.63K | $11.63K | $109.59K |
| Interest Expense | $4.37M | $3.00M | $2.60M | $2.52M | $1.96M | $1.76M | $1.43M | $1.12M | $698.00K | $620.00K | $542.00K | $478.00K | $204.59K | $205.11K | $202.51K | $202.84K | $201.46K | $190.55K | $211.05K | $254.95K |
| Depreciation and Amortization | $518.00K | $610.00K | $580.00K | $489.00K | $578.00K | $602.00K | $696.00K | $691.00K | $632.00K | $1.18M | $1.08M | $1.07M | $937.40K | $1.61M | $1.64M | $1.66M | $951.18K | $722.33K | $724.05K | $732.03K |
| EBITDA | $-33.48M | $-19.55M | $-24.76M | $-37.91M | $-24.91M | $-13.43M | $-21.39M | $-9.93M | $-5.20M | $-7.29M | $-7.83M | $-14.39M | $-10.42M | $-5.47M | $-4.71M | $-7.32M | $-15.07M | $-14.06M | $-12.98M | $-13.77M |
| EBITDA Ratio | -1147.93% | -439.50% | -676.74% | -1275.74% | -549.77% | -365.06% | -447.03% | -221.01% | -97.07% | -230.39% | -199.82% | -412.23% | -324.14% | -172.05% | -139.41% | -237.31% | -2037.83% | - | - | - |
| Operating Income | $-36.11M | $-29.19M | $-27.20M | $-28.80M | $-26.44M | $-14.89M | $-22.82M | $-9.23M | $-6.50M | $-8.83M | $-8.97M | $-14.47M | $-11.36M | $-7.08M | $-6.35M | $-9.00M | $-15.91M | $-14.81M | $-13.72M | $-14.65M |
| Operating Income Ratio | -1237.81% | -656.23% | -743.29% | -969.08% | -583.45% | -404.87% | -476.91% | -205.48% | -121.21% | -279.02% | -228.94% | -414.43% | -353.42% | -222.73% | -188.20% | -291.90% | -2151.56% | - | - | - |
| Total Other Income Expenses Net | $-2.26M | $6.03M | $-745.00K | $-12.13M | $-1.01M | $-899.00K | $-692.00K | $-2.51M | $-36.00K | $-261.00K | $-477.00K | $-1.47M | $-200.67K | $-200.89K | $-197.49K | $-182.15K | $-172.95K | $-155.91K | $-199.42K | $-145.36K |
| Income Before Tax | $-38.37M | $-23.16M | $-27.94M | $-40.93M | $-27.45M | $-15.79M | $-23.52M | $-11.74M | $-6.53M | $-9.09M | $-9.45M | $-15.94M | $-11.56M | $-7.28M | $-6.55M | $-9.18M | $-16.09M | $-14.97M | $-13.92M | $-14.79M |
| Income Before Tax Ratio | -1315.36% | -520.57% | -763.65% | -1377.12% | -605.83% | -429.31% | -491.37% | -261.41% | -121.88% | -287.27% | -241.12% | -456.56% | -359.66% | -229.06% | -194.06% | -297.80% | -2174.95% | - | - | - |
| Income Tax Expense | $- | $- | $- | $445.72K | $-2.40M | $862.00K | $145.00K | $1.39M | $-566.00K | $261.00K | $65.00K | $478.00K | $3.91K | $3.88K | $4.88K | $20.77K | $28.51K | $34.63K | $11.63K | $109.59K |
| Net Income | $-38.37M | $-23.16M | $-27.94M | $-40.93M | $-27.45M | $-15.79M | $-23.52M | $-13.13M | $-5.97M | $-9.35M | $-9.45M | $-15.94M | $-11.56M | $-7.28M | $-6.55M | $-9.18M | $-16.09M | $-14.97M | $-13.92M | $-14.79M |
| Net Income Ratio | -1315.36% | -520.57% | -763.65% | -1377.12% | -605.83% | -429.31% | -491.37% | -292.32% | -111.32% | -295.51% | -241.12% | -456.56% | -359.66% | -229.06% | -194.06% | -297.80% | -2174.95% | - | - | - |
| EPS | $-0.49 | $-0.30 | $-0.37 | $-0.54 | $-0.42 | $-0.24 | $-0.36 | $-0.20 | $-0.09 | $-0.15 | $-0.15 | $-0.30 | $-0.23 | $-0.14 | $-0.13 | $-0.21 | $-0.39 | $-0.40 | $-0.49 | $-0.52 |
| EPS Diluted | $-0.49 | $-0.30 | $-0.37 | $-0.54 | $-0.42 | $-0.24 | $-0.36 | $-0.20 | $-0.09 | $-0.15 | $-0.15 | $-0.30 | $-0.22 | $-0.14 | $-0.13 | $-0.21 | $-0.39 | $-0.40 | $-0.49 | $-0.52 |
| Weighted Average Shares Outstanding | 78.71M | 78.32M | 76.44M | 75.39M | 65.42M | 64.86M | 64.79M | 64.66M | 64.52M | 64.46M | 62.18M | 52.47M | 51.38M | 52.08M | 50.85M | 43.44M | 40.82M | 37.76M | 28.48M | 28.43M |
| Weighted Average Shares Outstanding Diluted | 78.71M | 78.32M | 76.44M | 75.39M | 65.42M | 64.86M | 64.79M | 64.66M | 64.52M | 64.46M | 62.18M | 52.47M | 52.24M | 52.08M | 50.85M | 43.44M | 40.82M | 37.76M | 28.48M | 28.43M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $176.48M | $83.68M | $93.28M | $57.49M | $65.32M |
| Short Term Investments | $- | $- | $- | $- | $- |
| Cash and Short Term Investments | $176.48M | $83.68M | $93.28M | $57.49M | $65.32M |
| Net Receivables | $2.72M | $4.06M | $5.02M | $2.99M | $- |
| Inventory | $241.00K | $- | $- | $- | $- |
| Other Current Assets | $5.67M | $2.16M | $1.51M | $792.38K | $752.45K |
| Total Current Assets | $185.10M | $89.90M | $99.81M | $61.28M | $66.07M |
| Property Plant Equipment Net | $12.48M | $6.18M | $6.25M | $7.43M | $9.45M |
| Goodwill | $3.90M | $3.90M | $3.90M | $3.90M | $3.90M |
| Intangible Assets | $3.16M | $3.43M | $3.73M | $4.39M | $5.53M |
| Goodwill and Intangible Assets | $7.06M | $7.33M | $7.63M | $8.29M | $9.44M |
| Long Term Investments | $- | $- | $-2.15M | $-2.52M | $-1.50M |
| Tax Assets | $- | $- | $2.15M | $2.52M | $1.50M |
| Other Non-Current Assets | $25.66M | $14.92M | $15.51M | $16.73M | $14.57M |
| Total Non-Current Assets | $45.21M | $28.43M | $29.39M | $32.45M | $33.46M |
| Other Assets | $- | $- | $- | $- | $- |
| Total Assets | $230.31M | $118.33M | $129.20M | $93.73M | $99.53M |
| Account Payables | $4.69M | $1.40M | $2.20M | $1.07M | $3.73M |
| Short Term Debt | $18.43M | $2.28M | $2.16M | $1.09M | $1.59M |
| Tax Payables | $- | $- | $- | $- | $- |
| Deferred Revenue | $- | $- | $- | $- | $4.65M |
| Other Current Liabilities | $18.66M | $14.88M | $4.44M | $5.17M | $6.42M |
| Total Current Liabilities | $41.78M | $18.55M | $8.80M | $7.33M | $11.74M |
| Long Term Debt | $6.59M | $2.36M | $23.38M | $14.99T | $15.55M |
| Deferred Revenue Non-Current | $- | $- | $-2.15M | $-2.52M | $-1.50M |
| Deferred Tax Liabilities Non-Current | $- | $- | $2.15M | $2.52M | $1.50M |
| Other Non-Current Liabilities | $104.67M | $50.12M | $6.59M | $-14.99T | $1.15M |
| Total Non-Current Liabilities | $111.26M | $52.49M | $29.98M | $21.14M | $16.71M |
| Other Liabilities | $- | $- | $- | $- | $- |
| Total Liabilities | $153.04M | $71.04M | $38.78M | $28.46M | $28.45M |
| Preferred Stock | $- | $- | $- | $- | $- |
| Common Stock | $85.00K | $69.00K | $64.00K | $52.29K | $43.34K |
| Retained Earnings | $-559.49M | $-429.10M | $-350.60M | $-309.58M | $-275.00M |
| Accumulated Other Comprehensive Income Loss | $- | $- | $- | $- | $0 |
| Other Total Stockholders Equity | $636.68M | $476.32M | $440.95M | $-51.87K | $346.04M |
| Total Stockholders Equity | $77.28M | $47.29M | $-350.60M | $-309.58M | $-275.00M |
| Total Equity | $77.28M | $47.29M | $-350.60M | $-309.58M | $-275.00M |
| Total Liabilities and Stockholders Equity | $230.31M | $118.33M | $-311.82M | $-281.12M | $-246.56M |
| Minority Interest | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $230.31M | $118.33M | $-311.82M | $-281.12M | $-246.56M |
| Total Investments | $- | $-1 | $-2.15M | $-2.52M | $-1.50M |
| Total Debt | $25.02M | $3.50M | $24.46M | $16.08M | $17.14M |
| Net Debt | $-151.46M | $-80.18M | $-68.82M | $-41.42M | $-48.17M |
Balance Sheet Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $176.48M | $204.37M | $133.09M | $157.86M | $83.68M | $76.22M | $88.20M | $94.41M | $93.28M | $98.32M | $103.84M | $57.79M | $57.49M | $64.05M | $67.89M | $53.64M | $65.32M | $79.55M | $23.59M | $40.13M |
| Short Term Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Cash and Short Term Investments | $176.48M | $204.37M | $133.09M | $157.86M | $83.68M | $76.22M | $88.20M | $94.41M | $93.28M | $98.32M | $103.84M | $57.79M | $57.49M | $64.05M | $67.89M | $53.64M | $65.32M | $79.55M | $23.59M | $40.13M |
| Net Receivables | $2.72M | $4.20M | $3.25M | $2.57M | $4.06M | $3.34M | $4.09M | $4.13M | $5.02M | $3.14M | $3.75M | $3.29M | $2.99M | $3.05M | $2.99M | $627.60K | $- | $- | $- | $- |
| Inventory | $241.00K | $38.00K | $7.21M | $3.52M | $1 | $- | $2 | $-4.13M | $- | $- | $1 | $- | $- | $1 | $1 | $1 | $- | $- | $- | $- |
| Other Current Assets | $5.67M | $5.60M | $3.71M | $3.99M | $2.16M | $3.42M | $601.00K | $2.29M | $1.51M | $3.20M | $1.81M | $1.75M | $792.38K | $375.69K | $439.47K | $814.05K | $752.45K | $1.10M | $750.02K | $884.92K |
| Total Current Assets | $185.10M | $214.21M | $147.26M | $167.94M | $89.90M | $82.98M | $92.89M | $99.69M | $99.81M | $103.06M | $108.50M | $61.95M | $61.28M | $67.48M | $71.32M | $55.08M | $66.07M | $80.65M | $24.34M | $41.01M |
| Property Plant Equipment Net | $12.48M | $9.15M | $7.86M | $7.17M | $6.18M | $6.21M | $6.08M | $6.36M | $6.25M | $6.13M | $6.49M | $6.96M | $7.43M | $7.93M | $8.42M | $8.89M | $9.45M | $10.09M | $10.72M | $11.39M |
| Goodwill | $3.90M | $3.90M | $3.90M | $3.90M | $3.90M | $3.90M | $3.90M | $3.90M | $3.90M | $3.90M | $3.90M | $3.90M | $3.90M | $3.90M | $3.90M | $3.90M | $3.90M | $- | $- | $- |
| Intangible Assets | $3.16M | $3.22M | $3.30M | $3.38M | $3.43M | $3.49M | $3.55M | $3.64M | $3.73M | $3.81M | $4.04M | $4.22M | $4.39M | $4.52M | $4.85M | $5.21M | $5.53M | $- | $- | $- |
| Goodwill and Intangible Assets | $7.06M | $7.12M | $7.20M | $7.28M | $7.33M | $7.39M | $7.46M | $7.55M | $7.63M | $7.71M | $7.94M | $8.13M | $8.29M | $8.42M | $8.76M | $9.11M | $9.44M | $- | $- | $- |
| Long Term Investments | $- | $- | $- | $- | $3.43M | $- | $- | $- | $-2.15M | $- | $- | $- | $-2.52M | $- | $- | $- | $- | $- | $- | $- |
| Tax Assets | $- | $- | $- | $- | $2.10M | $- | $- | $- | $2.15M | $- | $- | $- | $2.52M | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $25.66M | $22.40M | $15.04M | $14.73M | $11.49M | $15.05M | $15.16M | $15.33M | $15.51M | $15.67M | $16.15M | $16.49M | $14.21M | $16.47M | $15.88M | $15.37M | $14.57M | $378.04K | $378.04K | $381.04K |
| Total Non-Current Assets | $45.21M | $38.67M | $30.10M | $29.18M | $30.53M | $28.66M | $28.70M | $29.23M | $29.39M | $29.51M | $30.58M | $31.57M | $32.45M | $32.82M | $33.06M | $33.37M | $33.46M | $10.46M | $11.10M | $11.77M |
| Other Assets | $- | $- | $- | $- | $1 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Assets | $230.31M | $252.89M | $177.36M | $197.12M | $120.43M | $111.64M | $121.60M | $128.92M | $129.20M | $132.57M | $139.08M | $93.53M | $93.73M | $100.30M | $104.38M | $88.45M | $99.53M | $91.11M | $35.43M | $52.78M |
| Account Payables | $4.69M | $2.30M | $5.74M | $2.49M | $1.40M | $1.81M | $1.92M | $841.00K | $2.20M | $1.14M | $1.41M | $1.67M | $1.07M | $1.61M | $2.55M | $3.00M | $3.73M | $3.41M | $2.52M | $5.53M |
| Short Term Debt | $18.43M | $1.25M | $2.45M | $1.21M | $2.28M | $2.21M | $2.14M | $1.03M | $1.08M | $2.19M | $2.23M | $2.28M | $1.09M | $1.07M | $1.05M | $1.02M | $1.59M | $7.34M | $7.54M | $7.66M |
| Tax Payables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Revenue | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $4.65M | $- | $- | $- |
| Other Current Liabilities | $18.66M | $30.29M | $16.03M | $18.22M | $14.88M | $8.13M | $15.44M | $4.95M | $5.52M | $4.13M | $3.19M | $4.03M | $5.17M | $4.38M | $3.38M | $3.85M | $6.42M | $3.48M | $3.27M | $2.89M |
| Total Current Liabilities | $41.78M | $33.84M | $24.22M | $21.93M | $18.55M | $12.16M | $19.50M | $6.82M | $8.80M | $7.46M | $6.84M | $7.98M | $7.33M | $7.06M | $6.97M | $7.88M | $11.74M | $14.23M | $13.33M | $16.08M |
| Long Term Debt | $103.96M | $1.44M | $1.73M | $2.02M | $2.36M | $2.66M | $2.95M | $3.23M | $23.38M | $23.51M | $23.63M | $23.74M | $15.77T | $15.20M | $15.39M | $15.58M | $15.55M | $11.60M | $13.23M | $14.92M |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $-2.15M | $- | $- | $- | $-2.52M | $- | $- | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $2.10M | $- | $- | $- | $2.15M | $- | $- | $- | $2.52M | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $7.30M | $107.09M | $88.69M | $86.92M | $50.12M | $48.81M | $38.49M | $37.23M | $6.59M | $6.56M | $6.51M | $6.42M | $-15.77T | $5.07M | $3.00M | $2.08M | $1.15M | $- | $- | $- |
| Total Non-Current Liabilities | $111.26M | $108.53M | $90.42M | $88.93M | $54.59M | $51.48M | $41.45M | $40.46M | $29.98M | $30.07M | $30.14M | $30.16M | $21.14M | $20.27M | $18.39M | $17.66M | $16.71M | $11.60M | $13.23M | $14.92M |
| Other Liabilities | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities | $153.04M | $142.37M | $114.64M | $110.86M | $73.14M | $63.63M | $60.94M | $47.28M | $38.78M | $37.53M | $36.98M | $38.14M | $28.46M | $27.34M | $25.36M | $25.54M | $28.45M | $25.83M | $26.56M | $31.01M |
| Preferred Stock | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock | $85.00K | $85.00K | $76.00K | $76.00K | $69.00K | $65.00K | $65.00K | $65.00K | $64.00K | $64.00K | $64.00K | $53.00K | $52.29K | $51.98K | $51.98K | $43.35K | $43.34K | $37.75K | $28.37K | $28.37K |
| Retained Earnings | $-559.49M | $-521.12M | $-497.97M | $-470.03M | $-429.10M | $-401.65M | $-385.86M | $-362.34M | $-350.60M | $-344.06M | $-334.97M | $-325.52M | $-309.58M | $-298.02M | $-290.74M | $-284.19M | $-275.00M | $-258.92M | $-243.95M | $-230.03M |
| Accumulated Other Comprehensive Income Loss | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $0 | $-13.53M | $-12.81M | $-12.08M |
| Other Total Stockholders Equity | $636.68M | $631.56M | $560.61M | $556.21M | $476.32M | $449.59M | $446.45M | $443.92M | $440.95M | $439.03M | $437.01M | $380.86M | $374.79M | $370.93M | $369.71M | $347.05M | $346.04M | $324.16M | $252.79M | $251.77M |
| Total Stockholders Equity | $77.28M | $110.52M | $62.72M | $86.26M | $47.29M | $48.01M | $-385.86M | $-362.34M | $-350.60M | $95.03M | $102.11M | $55.39M | $65.27M | $72.96M | $79.02M | $62.91M | $71.09M | $65.28M | $8.87M | $21.77M |
| Total Equity | $77.28M | $110.52M | $62.72M | $86.26M | $47.29M | $48.01M | $-385.86M | $-362.34M | $-350.60M | $95.03M | $102.11M | $55.39M | $65.27M | $72.96M | $79.02M | $62.91M | $71.09M | $65.28M | $8.87M | $21.77M |
| Total Liabilities and Stockholders Equity | $230.31M | $252.89M | $177.36M | $197.12M | $120.43M | $111.64M | $-324.92M | $-315.06M | $-311.82M | $132.57M | $139.08M | $93.53M | $93.73M | $100.30M | $104.38M | $88.45M | $99.53M | $91.11M | $35.43M | $52.78M |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $230.31M | $252.89M | $177.36M | $197.12M | $120.43M | $111.64M | $-324.92M | $-315.06M | $-311.82M | $132.57M | $139.08M | $93.53M | $93.73M | $100.30M | $104.38M | $88.45M | $99.53M | $91.11M | $35.43M | $52.78M |
| Total Investments | $- | $- | $- | $- | $3.43M | $- | $- | $- | $-2.15M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Debt | $122.39M | $2.69M | $2.95M | $3.23M | $3.50M | $3.77M | $4.02M | $4.26M | $24.46M | $24.61M | $24.74M | $24.88M | $16.08M | $16.27M | $16.44M | $16.60M | $17.14M | $18.94M | $20.77M | $22.58M |
| Net Debt | $-54.09M | $-201.68M | $-130.14M | $-154.63M | $-80.18M | $-72.46M | $-84.18M | $-90.15M | $-68.82M | $-73.71M | $-79.10M | $-32.91M | $-41.42M | $-47.79M | $-51.45M | $-37.03M | $-48.17M | $-60.61M | $-2.82M | $-17.54M |
Annual Cash Flow
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Net Income | $-130.39M | $-78.50M | $-41.02M | $-34.58M | $-59.76M |
| Depreciation and Amortization | $2.20M | $2.18M | $3.65M | $5.61M | $3.13M |
| Deferred Income Tax | $- | $- | $- | $43.95K | $10.80K |
| Stock Based Compensation | $18.81M | $10.09M | $9.30M | $6.75M | $3.95M |
| Change in Working Capital | $- | $5.87M | $-2.16M | $-12.38M | $-1.71M |
| Accounts Receivables | $1.34M | $956.00K | $-2.03M | $-2.99M | $- |
| Inventory | $-241.00K | $- | $- | $-1.73M | $- |
| Accounts Payables | $2.33M | $-1.15M | $814.00K | $-7.56M | $-297.16K |
| Other Working Capital | $- | $6.07M | $-945.00K | $-102.73K | $-1.41M |
| Other Non Cash Items | $15.97M | $18.80M | $1.64M | $522.27K | $235.53K |
| Net Cash Provided by Operating Activities | $-93.42M | $-41.56M | $-28.59M | $-34.04M | $-54.14M |
| Investments in Property Plant and Equipment | $-4.95M | $-1.29M | $-592.00K | $-107.22K | $-752.09K |
| Acquisitions Net | $- | $- | $5.00K | $- | $1.00M |
| Purchases of Investments | $- | $- | $- | $- | $- |
| Sales Maturities of Investments | $- | $- | $- | $- | $- |
| Other Investing Activities | $-3.49M | $-10.00M | $5.00K | $- | $- |
| Net Cash Used for Investing Activities | $-8.44M | $-11.29M | $-587.00K | $-107.22K | $247.91K |
| Debt Repayment | $52.50M | $19.37M | $8.96M | $-419.84K | $-6.77M |
| Common Stock Issued | $138.55M | $24.24M | $54.46M | $21.71M | $71.23M |
| Common Stock Repurchased | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- |
| Other Financing Activities | $3.61M | $-363.00K | $1.55M | $5.03M | $-1.04M |
| Net Cash Used Provided by Financing Activities | $194.66M | $43.25M | $64.96M | $26.32M | $63.42M |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $- |
| Net Change in Cash | $92.80M | $-9.60M | $35.79M | $-7.82M | $9.52M |
| Cash at End of Period | $176.48M | $83.68M | $93.28M | $57.49M | $65.32M |
| Cash at Beginning of Period | $83.68M | $93.28M | $57.49M | $65.32M | $55.80M |
| Operating Cash Flow | $-93.42M | $-41.56M | $-28.59M | $-34.04M | $-54.14M |
| Capital Expenditure | $-4.95M | $-1.29M | $-592.00K | $-107.22K | $-752.09K |
| Free Cash Flow | $-98.37M | $-42.85M | $-29.18M | $-34.14M | $-54.90M |
Cash Flow Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $-38.37M | $-23.16M | $-27.94M | $-40.93M | $-27.45M | $-15.79M | $-23.52M | $-11.74M | $-6.53M | $-9.09M | $-9.45M | $-15.94M | $-11.56M | $-7.28M | $-6.55M | $-9.18M | $-16.09M | $-14.97M | $-13.92M | $-14.79M |
| Depreciation and Amortization | $518.00K | $610.00K | $580.00K | $489.00K | $578.00K | $514.00K | $589.00K | $569.00K | $566.00K | $1.13M | $1.01M | $947.00K | $871.63K | $1.55M | $1.59M | $1.61M | $951.18K | $722.33K | $724.05K | $732.03K |
| Deferred Income Tax | $- | $- | $- | $- | $-5.03M | $- | $- | $- | $- | $- | $- | $- | $14.83K | $-1 | $29.12K | $- | $10.80K | $- | $- | $- |
| Stock Based Compensation | $5.03M | $4.88M | $4.37M | $4.52M | $2.55M | $2.49M | $2.50M | $2.55M | $1.82M | $1.65M | $1.65M | $4.18M | $3.82M | $1.22M | $953.22K | $745.00K | $1.01M | $1.08M | $988.12K | $878.96K |
| Change in Working Capital | $3.99M | $120.00K | $-2.39M | $-3.07M | $6.34M | $-631.00K | $3.35M | $-3.19M | $-648.00K | $349.00K | $-1.83M | $-32.00K | $-849.64K | $-1.46M | $-4.34M | $-5.73M | $-32.75K | $599.58K | $-963.50K | $-1.31M |
| Accounts Receivables | $1.48M | $-953.00K | $-679.00K | $1.49M | $-723.00K | $757.00K | $36.00K | $886.00K | $-1.88M | $617.00K | $-466.00K | $-297.00K | $60.67K | $-58.78K | $-2.36M | $-627.60K | $- | $- | $- | $- |
| Inventory | $-203.00K | $7.17M | $-3.69M | $-3.52M | $- | $- | $- | $- | $- | $- | $- | $- | $-898.82K | $463.04K | $-288.53K | $-1.01M | $- | $- | $- | $- |
| Accounts Payables | $2.55M | $-3.45M | $2.92M | $303.00K | $-596.00K | $-176.00K | $1.11M | $-1.50M | $1.02M | $-314.00K | $-347.00K | $458.00K | $-1.11M | $-2.31M | $-1.81M | $-2.33M | $-430.68K | $882.72K | $-2.95M | $2.21M |
| Other Working Capital | $162.00K | $-2.65M | $-936.00K | $-1.35M | $7.66M | $-1.21M | $2.19M | $609.00K | $216.00K | $46.00K | $-1.01M | $-193.00K | $1.10M | $445.59K | $127.99K | $-1.77M | $397.93K | $-283.14K | $1.99M | $-3.52M |
| Other Non Cash Items | $8.02M | $-7.54M | $2.72M | $21.34M | $7.02M | $1.86M | $11.52M | $3.35M | $194.00K | $193.00K | $192.00K | $1.06M | $142.90K | $139.20K | $62.98K | $177.20K | $63.26K | $56.64K | $58.28K | $57.35K |
| Net Cash Provided by Operating Activities | $-20.81M | $-25.08M | $-22.66M | $-24.87M | $-15.98M | $-11.56M | $-5.56M | $-8.46M | $-4.60M | $-5.77M | $-8.43M | $-9.78M | $-7.56M | $-5.83M | $-8.26M | $-12.39M | $-14.09M | $-12.51M | $-13.11M | $-14.44M |
| Investments in Property Plant and Equipment | $-1.29M | $-1.75M | $-1.29M | $-624.00K | $-206.00K | $-10.47M | $-243.00K | $-366.00K | $-491.00K | $-94.00K | $-7.00K | $- | $-19.98K | $-240 | $-34.82K | $-52.42K | $-38.97K | $-122.50K | $-408.40K | $-182.22K |
| Acquisitions Net | $- | $- | $- | $- | $-2.00K | $- | $- | $2.00K | $- | $- | $5.00K | $- | $- | $- | $- | $- | $1.00B | $- | $- | $- |
| Purchases of Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Sales Maturities of Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Investing Activities | $-3.49M | $- | $- | $- | $-10.00M | $-10.00M | $- | $2.00K | $- | $- | $5.00K | $- | $- | $- | $- | $- | $-999.00M | $- | $- | $- |
| Net Cash Used for Investing Activities | $-4.78M | $-1.75M | $-1.29M | $-624.00K | $-206.00K | $-10.47M | $-243.00K | $-364.00K | $-491.00K | $-94.00K | $-2.00K | $- | $-19.98K | $- | $-34.82K | $-52.42K | $961.03K | $-122.50K | $-408.40K | $-182.22K |
| Debt Repayment | $-4.88M | $32.46M | $-27.00K | $24.95M | $-26.00K | $9.90M | $-25.00K | $9.52M | $-76.00K | $-75.00K | $-78.00K | $9.19M | $-90.14K | $-80.16K | $-80.95K | $-168.59K | $-1.66M | $-1.70M | $-1.69M | $-1.72M |
| Common Stock Issued | $-342.00K | $64.03M | $32.00K | $74.87M | $24.24M | $652.00K | $32.00K | $414.00K | $1 | $371.00K | $622.00K | $621.00K | $21.71T | $- | $21.71M | $494.00K | $71.15B | $70.50M | $- | $725.40K |
| Common Stock Repurchased | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $2.93M | $1.62M | $-819.00K | $-148.00K | $-570.00K | $160.00K | $-416.00K | $431.00K | $133.00K | $423.00K | $54.55M | $897.00K | $1.11M | $2.08M | $918.36K | $927.10K | $549.84K | $-200.80K | $-1.33M | $-57.47K |
| Net Cash Used Provided by Financing Activities | $-2.30M | $98.10M | $-814.00K | $99.67M | $23.64M | $10.06M | $-409.00K | $9.95M | $57.00K | $348.00K | $54.48M | $10.08M | $1.02M | $1.99M | $22.55M | $758.81K | $-1.11M | $68.60M | $-3.02M | $-1.05M |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $57.49T | $- | $- | $- | $- | $- | $- | $- |
| Net Change in Cash | $-27.89M | $71.28M | $-24.77M | $74.18M | $7.45M | $-11.97M | $-6.22M | $1.13M | $-5.04M | $-5.52M | $46.05M | $300.00K | $-6.56M | $-3.84M | $14.25M | $-11.68M | $-14.23M | $55.96M | $-16.54M | $-15.67M |
| Cash at End of Period | $176.48M | $204.37M | $133.09M | $157.86M | $83.68M | $76.22M | $88.20M | $94.41M | $93.28M | $98.32M | $103.84M | $57.79M | $57.49M | $64.05M | $67.89M | $53.64M | $65.32M | $79.55M | $23.59M | $40.13M |
| Cash at Beginning of Period | $204.37M | $133.09M | $157.86M | $83.68M | $76.22M | $88.20M | $94.41M | $93.28M | $98.32M | $103.84M | $57.79M | $57.49M | $64.05M | $67.89M | $53.64M | $65.32M | $79.55M | $23.59M | $40.13M | $55.80M |
| Operating Cash Flow | $-20.81M | $-25.08M | $-22.66M | $-24.87M | $-15.98M | $-11.56M | $-5.56M | $-8.46M | $-4.60M | $-5.77M | $-8.43M | $-9.78M | $-7.56M | $-5.83M | $-8.26M | $-12.39M | $-14.09M | $-12.51M | $-13.11M | $-14.44M |
| Capital Expenditure | $-4.79M | $-1.75M | $-1.29M | $-624.00K | $-206.00K | $-10.47M | $-243.00K | $-366.00K | $-491.00K | $-94.00K | $-7.00K | $- | $-19.98K | $-240 | $-34.82K | $-52.42K | $-38.97K | $-122.50K | $-408.40K | $-182.22K |
| Free Cash Flow | $-25.60M | $-26.83M | $-23.95M | $-25.49M | $-16.19M | $-22.04M | $-5.81M | $-8.82M | $-5.09M | $-5.87M | $-8.44M | $-9.78M | $-7.58M | $-5.83M | $-8.30M | $-12.44M | $-14.13M | $-12.63M | $-13.52M | $-14.62M |
Liquidia Dividends
Explore Liquidia's dividend history, including dividend yield, payout ratio, and historical payments.
Liquidia News
Read the latest news about Liquidia, including recent articles, headlines, and updates.
Liquidia Corporation (LQDA) Q4 2024 Earnings Call Transcript
Liquidia Corporation (NASDAQ:LQDA ) Q4 2024 Earnings Conference Call March 19, 2025 8:30 AM ET Company Participants Jason Adair - Chief Business Officer Roger Jeffs - CEO Michael Kaseta - COO and CFO Rajeev Saggar - Chief Medical Officer Scott Moomaw - Chief Commercial Officer Rusty Schundler - General Counsel Conference Call Participants Julian Harrison - BTIG Serge Belanger - Needham Ryan Deschner - Raymond James Greg Harrison - Scotiabank Cory Jubinville - LifeSci Capital Operator Good morning. And welcome everyone to Liquidia Corporation Full Year 2024 Financial Results and Corporate Update Conference Call.
Liquidia Corporation Reports Full Year 2024 Financial Results and Provides Corporate Update
Targeting final FDA approval of YUTREPIA™ after expiration of regulatory exclusivity on May 23, 2025 Advancing pipeline of inhaled treprostinil products in clinical studies Strengthened financial position by up to $100 million via amendment to existing financing agreement with HealthCare Royalty Partners (HCRx) Company to host webcast today at 8:30 a.m. ET MORRISVILLE, N.C.
Liquidia Corporation to Report Full Year 2024 Financial Results on March 19, 2025
MORRISVILLE, N.C., March 12, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, announced today that it will report its full year 2024 financial results on Wednesday, March 19, 2025.
Liquidia named a top pick for 2025 at Needham
Needham analyst Serge Belanger named Liquidia a top pick for 2025 with a Buy rating and $19 price target. The stock was also the analyst's top pick for 2024, and "disappointed" with a negative 2% performance mostly due to the mid-August setback when the FDA delayed approval by retroactively granting Tyvaso DPI a three year exclusivity dating to 2022, Needham points out. The firm says its "investment thesis is stronger now than a year ago." It has a "clear line of sight" for FDA approval of Yutrepia in both pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease by May 23. Yutrepia will launch into an opportunity that will have grown into a $2B market by mid-2025, on its way to over $3B-$4B by 2030, contends the firm.
Does Liquidia Technologies (LQDA) Have the Potential to Rally 132.54% as Wall Street Analysts Expect?
The mean of analysts' price targets for Liquidia Technologies (LQDA) points to a 132.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Wall Street Analysts See a 126.13% Upside in Liquidia Technologies (LQDA): Can the Stock Really Move This High?
The consensus price target hints at a 126.1% upside potential for Liquidia Technologies (LQDA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Liquidia Corporation: Resilience In The Face Of Formidable Opposition Can Pay Off
Liquidia's Yutrepia, a competitor to United Therapeutics' Tyvaso, faces potential market entry in 2025, with promising clinical data and a competitive therapeutic profile. Despite financial challenges and intense competition, Liquidia's low valuation and upcoming product launches present a compelling investment opportunity. Liquidia's legal battles with United Therapeutics are nearing resolution, potentially clearing the path for Yutrepia's commercial launch by mid-2025.
Liquidia Corporation (LQDA) Q3 2024 Earnings Call Transcript
Liquidia Corporation (NASDAQ:LQDA ) Q3 2024 Earnings Conference Call November 13, 2024 8:30 AM ET Company Participants Jason Adair - Chief Business Officer Roger Jeffs - Chief Executive Officer Rusty Schundler - General Counsel Rajeev Saggar - Chief Medical Officer Michael Kaseta - Chief Operating Officer & Chief Financial Officer Scott Moomaw - Chief Commercial Officer Conference Call Participants Julian Harrison - BTIG Jason Gerberry - Bank of America Greg Harrison - Scotiabank Kambiz Yazdi - Jefferies Cory Jubinville - LifeSci Capital Matt Kaplan - Ladenburg Thalmann Ryan Deschner - Raymond James Operator Good morning and welcome everyone to Liquidia Corporation Third Quarter 2024 Financial Results and Corporate Update Conference Call. My name is Michelle [ph] and I will be your conference operator today.
Liquidia Corporation Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Received tentative approval from the FDA for YUTREPIA™ (treprostinil) inhalation powder for both pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) U.S. Supreme Court rejected final appeal of ‘793 patent decision, marking victories with respect to three patents originally asserted final and not subject to further appeal Strengthened balance sheet by raising approximately $100 million in additional capital MORRISVILLE, N.C., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today reported financial results for the third quarter ended September 30, 2024.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Liquidia Corporation - LQDA
NEW YORK, NY / ACCESSWIRE / November 4, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Liquidia Corporation ("Liquidia" or the "Company") (NASDAQ:LQDA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for LQDA.